Please enable JavaScript to view the comments powered by Disqus.
Slide Show

1 of 6

Practical Advice from

5 Biotech Stocks That Are "Strong Buys"

Getty Images


According to top analysts on the Street, these five “Strong Buy” biotech stocks are primed for outsized growth in the next 12 months.

Biotechs often present intriguing, and potentially lucrative, investment opportunities. Share prices can explode on positive trial results or key regulatory approvals. However, buyers beware: These rewards can disappear just as quickly if critical data disappoints. To minimize this risk, we specifically searched for stocks with a high degree of confidence from Wall Street’s top analysts.

In this case, we used the popular Trending Stocks tool to filter for best-rated stocks in the last week, regardless of market capitalization. The best part about this tool is that it clearly displays the upside potential from the current share price to the average analyst price target.


So we crunched the data and pinpointed these five compelling biotech stocks that are trending right now. All five stocks share a bullish Strong Buy analyst consensus rating. Note that this is based only on analyst ratings from the last three months.

With this in mind, let’s delve deeper into why the Street is so bullish on these stocks right now:

SEE ALSO FROM KIPLINGER: 20 of the Best Stocks You Probably Haven't Heard Of

Prices and data are from the original InvestorPlace story published on Mar. 14. Click on ticker-symbol links in each slide for current prices and more.

This slide show is from InvestorPlace, not the Kiplinger editorial staff.


View as One Page

Sponsored Financial Content